Summary
Global Market Direct’s pharmaceuticals report, “Antares Pharma - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. It also gives a complete picture of the company’s future therapy areas of focus.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Global Markets Direct’s team of industry experts.
Scope
- Antares Pharma - company overview including business description, key employees, and other facts.
- Review of current pipeline of Antares Pharma human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, for the pharmaceutical markets across the globe.
- Product profiles for late stage and clinical stage products of Antares Pharma with complete description of the product’s developmental history, mechanism of action, clinical trials, major milestones and others.
- Recent updates of the Antares Pharma’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Antares Pharma’s strategic position with total access to a detailed intelligence on its product pipeline.
- Assess the growth potential of Antares Pharma in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Antares Pharma’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Antares Pharma.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Antares Pharma and identify potential opportunities in those areas.
- Do deals with an understanding of the mergers and partnerships that have shaped the sector.
Global Market Direct’s pharmaceuticals report, “Antares Pharma - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. It also gives a complete picture of the company’s future therapy areas of focus.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Global Markets Direct’s team of industry experts.
Scope
- Antares Pharma - company overview including business description, key employees, and other facts.
- Review of current pipeline of Antares Pharma human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, for the pharmaceutical markets across the globe.
- Product profiles for late stage and clinical stage products of Antares Pharma with complete description of the product’s developmental history, mechanism of action, clinical trials, major milestones and others.
- Recent updates of the Antares Pharma’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Antares Pharma’s strategic position with total access to a detailed intelligence on its product pipeline.
- Assess the growth potential of Antares Pharma in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Antares Pharma’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Antares Pharma.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Antares Pharma and identify potential opportunities in those areas.
- Do deals with an understanding of the mergers and partnerships that have shaped the sector.
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 list of Figures
2 INTRODUCTION
3 ANTARES PHARMA SNAPSHOT
3.1 Business Description
4 ANTARES PHARMA- RESEARCH AND DEVELOPMENT OVERVIEW
4.1 Key Therapeutic Areas
5 ANTARES PHARMA- PIPELINE REVIEW
5.1 Pipeline Products by Stage of Development
5.2 Pipeline Products-Monotherapy
5.3 Pipeline Products-Combination Treatment Modalities
6 ANTARES PHARMA PIPELINE PRODUCTS GLANCE
6.1 Antares Pharma Phase II Pipeline
6.2 Antares Pharma Phase I Pipeline
6.3 Antares Pharma Pre-Clinical Pipeline
7 ANTARES PHARMA - DRUG PROFILES
7.1 Product
7.1.1 Product Description
7.1.2 Mechanism of Action
7.1.3 R&D Progress
8 ANTARES PHARMA PIPELINE ANALYSIS
8.1 Antares Pharma Pipeline Products by Therapeutic Class
8.2 Antares Pharma Pipeline Products by Target
8.3 Antares Pharma Pipeline by Route of Administration
8.4 Antares Pharma Pipeline Products by Molecule Type
9 ANTARES PHARMA- RECENT PIPELINE UPDATES
10 ANTARES PHARMA- DORMANT PIPELINE PROJECTS
10.1 Feature on Dormant Projects
11 ANTARES PHARMA- DISCONTINUED PIPELINE PRODUCTS
11.1 Discontinued Pipeline Product Profiles
11.1.1 Product
12 ANTARES PHARMA – FEATURED NEWS
13 ANTARES PHARMA STATEMENT
13.1 Antares Pharma - Locations and Subsidiaries
14 APPENDIX
14.1 Global Markets Direct Research Methodology
14.2 Coverage
14.3 Secondary Research
14.4 Primary Research
14.5 Models
14.6 Expert Panels
14.7 Contact Us
14.8 Disclaimer
LIST OF TABLES
Table 1: Antares Pharma - Key Information
Table 2: Antares Pharma - Key Facts
Table 3: Antares Pharma - Key Therapeutic Areas
Table 4: Antares Pharma - Pipeline by Stage of Development,
Table 5: Antares Pharma - Monotherapy Products in Pipeline,
Table 6: Antares Pharma - Combination Treatment Modalities in Pipeline,
Table 7: Antares Pharma - Phase II Pipeline,
Table 8: Antares Pharma - Phase I Pipeline,
Table 9: Antares Pharma - Pre-Clinical Pipeline,
Table 10: Antares Pharma - Pipeline By Therapeutic Class
Table 11: Antares Pharma - Pipeline By Target
Table 12: Antares Pharma - Pipeline By Route of Administration
Table 13: Antares Pharma - Pipeline By Molecule Type
Table 14: Antares Pharma - Recent Pipeline Updates
Table 15: Antares Pharma - Dormant Pipeline Projects
LIST OF FIGURES
Figure 1: Antares Pharma - Research and Development Overview
Figure 2: Antares Pharma - Pipeline by Stage of Development,
Figure 3: Antares Pharma - Monotherapy Products in Pipeline,
Figure 4: Antares Pharma - Combination Treatment Modalities in Pipeline,
Figure 5: Antares Pharma - Pipeline By Therapeutic Class and Stage of Development
Figure 6: Antares Pharma - Pipeline By Therapeutic Class
Figure 7: Antares Pharma - Pipeline By Target and Stage of Development
Figure 8: Antares Pharma - Pipeline By Target
Figure 9: Antares Pharma - Pipeline By Route of Administration and Stage of Development
Figure 10: Antares Pharma - Pipeline By Route of Administration
Figure 11: Antares Pharma - Pipeline By Molecule Type and Stage of Development
Figure 12: Antares Pharma - Pipeline By Molecule Type
COMPANIES MENTIONED
Antares Pharma
1.1 List of Tables
1.2 list of Figures
2 INTRODUCTION
3 ANTARES PHARMA SNAPSHOT
3.1 Business Description
4 ANTARES PHARMA- RESEARCH AND DEVELOPMENT OVERVIEW
4.1 Key Therapeutic Areas
5 ANTARES PHARMA- PIPELINE REVIEW
5.1 Pipeline Products by Stage of Development
5.2 Pipeline Products-Monotherapy
5.3 Pipeline Products-Combination Treatment Modalities
6 ANTARES PHARMA PIPELINE PRODUCTS GLANCE
6.1 Antares Pharma Phase II Pipeline
6.2 Antares Pharma Phase I Pipeline
6.3 Antares Pharma Pre-Clinical Pipeline
7 ANTARES PHARMA - DRUG PROFILES
7.1 Product
7.1.1 Product Description
7.1.2 Mechanism of Action
7.1.3 R&D Progress
8 ANTARES PHARMA PIPELINE ANALYSIS
8.1 Antares Pharma Pipeline Products by Therapeutic Class
8.2 Antares Pharma Pipeline Products by Target
8.3 Antares Pharma Pipeline by Route of Administration
8.4 Antares Pharma Pipeline Products by Molecule Type
9 ANTARES PHARMA- RECENT PIPELINE UPDATES
10 ANTARES PHARMA- DORMANT PIPELINE PROJECTS
10.1 Feature on Dormant Projects
11 ANTARES PHARMA- DISCONTINUED PIPELINE PRODUCTS
11.1 Discontinued Pipeline Product Profiles
11.1.1 Product
12 ANTARES PHARMA – FEATURED NEWS
13 ANTARES PHARMA STATEMENT
13.1 Antares Pharma - Locations and Subsidiaries
14 APPENDIX
14.1 Global Markets Direct Research Methodology
14.2 Coverage
14.3 Secondary Research
14.4 Primary Research
14.5 Models
14.6 Expert Panels
14.7 Contact Us
14.8 Disclaimer
LIST OF TABLES
Table 1: Antares Pharma - Key Information
Table 2: Antares Pharma - Key Facts
Table 3: Antares Pharma - Key Therapeutic Areas
Table 4: Antares Pharma - Pipeline by Stage of Development,
Table 5: Antares Pharma - Monotherapy Products in Pipeline,
Table 6: Antares Pharma - Combination Treatment Modalities in Pipeline,
Table 7: Antares Pharma - Phase II Pipeline,
Table 8: Antares Pharma - Phase I Pipeline,
Table 9: Antares Pharma - Pre-Clinical Pipeline,
Table 10: Antares Pharma - Pipeline By Therapeutic Class
Table 11: Antares Pharma - Pipeline By Target
Table 12: Antares Pharma - Pipeline By Route of Administration
Table 13: Antares Pharma - Pipeline By Molecule Type
Table 14: Antares Pharma - Recent Pipeline Updates
Table 15: Antares Pharma - Dormant Pipeline Projects
LIST OF FIGURES
Figure 1: Antares Pharma - Research and Development Overview
Figure 2: Antares Pharma - Pipeline by Stage of Development,
Figure 3: Antares Pharma - Monotherapy Products in Pipeline,
Figure 4: Antares Pharma - Combination Treatment Modalities in Pipeline,
Figure 5: Antares Pharma - Pipeline By Therapeutic Class and Stage of Development
Figure 6: Antares Pharma - Pipeline By Therapeutic Class
Figure 7: Antares Pharma - Pipeline By Target and Stage of Development
Figure 8: Antares Pharma - Pipeline By Target
Figure 9: Antares Pharma - Pipeline By Route of Administration and Stage of Development
Figure 10: Antares Pharma - Pipeline By Route of Administration
Figure 11: Antares Pharma - Pipeline By Molecule Type and Stage of Development
Figure 12: Antares Pharma - Pipeline By Molecule Type
COMPANIES MENTIONED
Antares Pharma
